Radiology of fibrosis part III: genitourinary system.
Fibrosis
Imaging
Thoracic organs
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
received:
12
02
2024
accepted:
20
05
2024
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
3
7
2024
Statut:
epublish
Résumé
Fibrosis is a pathological process involving the abnormal deposition of connective tissue, resulting from improper tissue repair in response to sustained injury caused by hypoxia, infection, or physical damage. It can impact any organ, leading to their dysfunction and eventual failure. Additionally, tissue fibrosis plays an important role in carcinogenesis and the progression of cancer.Early and accurate diagnosis of organ fibrosis, coupled with regular surveillance, is essential for timely disease-modifying interventions, ultimately reducing mortality and enhancing quality of life. While extensive research has already been carried out on the topics of aberrant wound healing and fibrogenesis, we lack a thorough understanding of how their relationship reveals itself through modern imaging techniques.This paper focuses on fibrosis of the genito-urinary system, detailing relevant imaging technologies used for its detection and exploring future directions.
Identifiants
pubmed: 38961396
doi: 10.1186/s12967-024-05333-1
pii: 10.1186/s12967-024-05333-1
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
616Informations de copyright
© 2024. The Author(s).
Références
Chandler C, Liu T, Buckanovich R, Coffman LG. The double edge sword of fibrosis in cancer. Transl Res Jul. 2019;209:55–67. https://doi.org/10.1016/j.trsl.2019.02.006 .
doi: 10.1016/j.trsl.2019.02.006
Roman J, Barnes TR, Kervitsky DJ et al. May. The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities. Am J Med Sci. 2019;357(5):405–410. https://doi.org/10.1016/j.amjms.2019.02.014 .
Kumar V, Abbas AK, Aster JC. Robbins and Cotran: Pathologic Basis of Disease. 8th Edition ed. Elsevier Saunders, c2005.
Henderson NCRF, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020;587(7835):555–66. https://doi.org/10.1038/s41586-020-2938-9 .
doi: 10.1038/s41586-020-2938-9
pubmed: 33239795
pmcid: 8034822
CGMLDR SG. In: Fitridge R, Thompson M, eds. Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. University of Adelaide Press © The Contributors 2011.; 2011.
Reinke JM, Sorg H. Wound repair and regeneration. Eur Surg Res. 2012;49(1):35–43. https://doi.org/10.1159/000339613 .
doi: 10.1159/000339613
pubmed: 22797712
Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol Life Sci Oct. 2016;73(20):3861–85. https://doi.org/10.1007/s00018-016-2268-0 .
doi: 10.1007/s00018-016-2268-0
Bitto N, La Liguori E. Coagulation, Microenvironment and Liver Fibrosis. Cells Jul. 2018;24(8). https://doi.org/10.3390/cells7080085 .
Fiorucci S, Antonelli E, Distrutti E, et al. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatol Feb. 2004;39(2):365–75. https://doi.org/10.1002/hep.20054 .
doi: 10.1002/hep.20054
Pant A, Kopec AK, Luyendyk JP. Role of the blood coagulation cascade in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol. Aug 1. 2018;315(2):G171-g176. https://doi.org/10.1152/ajpgi.00402.2017 .
Gonzalez AC, Costa TF, Andrade ZA, Medrado AR. Wound healing - A literature review. Bras Dermatol Sep-Oct. 2016;91(5):614–20. https://doi.org/10.1590/abd1806-4841.20164741 .
doi: 10.1590/abd1806-4841.20164741
Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118. https://doi.org/10.1146/annurev-pathol-121808-102144 .
doi: 10.1146/annurev-pathol-121808-102144
pubmed: 20078217
Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, Horowitz JC. Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol Oct. 2009;41(4):484–93. https://doi.org/10.1165/rcmb.2008-0447OC .
doi: 10.1165/rcmb.2008-0447OC
Hinz B, Gabbiani G. Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives. F1000 Biol Rep. Nov 11 2010;2:78. https://doi.org/10.3410/b2-78 .
Djudjaj S, Boor P. Cellular and molecular mechanisms of kidney fibrosis. Mol Aspects Med Feb. 2019;65:16–36. https://doi.org/10.1016/j.mam.2018.06.002 .
doi: 10.1016/j.mam.2018.06.002
Jing H, Tang S, Lin S, et al. Adiponectin in renal fibrosis. Aging (Albany NY) Feb. 2020;17(5):4660–72. https://doi.org/10.18632/aging.102811 .
doi: 10.18632/aging.102811
Sato Y, Yanagita M. Resident fibroblasts in the kidney: a major driver of fibrosis and inflammation. Inflamm Regen. 2017;37:17. https://doi.org/10.1186/s41232-017-0048-3 .
doi: 10.1186/s41232-017-0048-3
pubmed: 29259716
Hamm LL, Batuman V. Edema in the nephrotic syndrome: new aspect of an old enigma. J Am Soc Nephrol. Dec 2003;14(12):3288–9. https://doi.org/10.1097/01.asn.0000102671.77794.33 .
Siddall EC, Radhakrishnan J. The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int Sep. 2012;82(6):635–42. https://doi.org/10.1038/ki.2012.180 .
doi: 10.1038/ki.2012.180
Leong SS, Wong JHD, Md Shah MN, Vijayananthan A, Jalalonmuhali M, Ng KH. Shear wave elastography in the evaluation of renal parenchymal stiffness in patients with chronic kidney disease. Br J Radiol Sep. 2018;91(1089):20180235. https://doi.org/10.1259/bjr.20180235 .
doi: 10.1259/bjr.20180235
Jiang K, Ferguson CM, Lerman LO. Noninvasive assessment of renal fibrosis by magnetic resonance imaging and ultrasound techniques. Transl Res Jul. 2019;209:105–20. https://doi.org/10.1016/j.trsl.2019.02.009 .
doi: 10.1016/j.trsl.2019.02.009
Grenier N, Gennisson JL, Cornelis F, Le Bras Y, Couzi L. Renal ultrasound elastography. Diagn Interv Imaging May. 2013;94(5):545–50. https://doi.org/10.1016/j.diii.2013.02.003 .
doi: 10.1016/j.diii.2013.02.003
Iyama T, Sugihara T, Takata T, Isomoto H. Renal Ultrasound Elastography: a review of the previous reports on chronic kidney diseases. Appl Sci. 2021;11(20):9677.
doi: 10.3390/app11209677
Lin HY, Lee YL, Lin KD, et al. Association of Renal Elasticity and renal function progression in patients with chronic kidney Disease evaluated by real-time Ultrasound Elastography. Sci Rep Feb. 2017;27:7:43303. https://doi.org/10.1038/srep43303 .
doi: 10.1038/srep43303
Li J, An C, Kang L, Mitch WE, Wang Y. Recent advances in magnetic Resonance Imaging Assessment of Renal Fibrosis. Adv Chronic Kidney Dis May. 2017;24(3):150–3. https://doi.org/10.1053/j.ackd.2017.03.005 .
doi: 10.1053/j.ackd.2017.03.005
Ali A, Bhan C, Malik MB, Ahmad MQ, Sami SA. The Prevention and Management of Contrast-induced Acute Kidney Injury: A Mini-review of the Literature. Cureus. Sep 11. 2018;10(9):e3284. https://doi.org/10.7759/cureus.3284 .
Wu MJ, Tsai SF. Patients with different stages of chronic kidney Disease Undergoing Intravenous contrast-enhanced computed tomography-the incidence of contrast-Associated Acute kidney Injury. Diagnostics (Basel) Mar. 2022;30(4). https://doi.org/10.3390/diagnostics12040864 .
Warner L, Yin M, Glaser KJ, et al. Noninvasive in vivo assessment of renal tissue elasticity during graded renal ischemia using MR Elastography. Invest Radiol Aug. 2011;46(8):509–14. https://doi.org/10.1097/RLI.0b013e3182183a95 .
doi: 10.1097/RLI.0b013e3182183a95
Güven AT, Idilman IS, Cebrayilov C, et al. Evaluation of renal fibrosis in various causes of glomerulonephritis by MR Elastography: a clinicopathologic comparative analysis. Abdom Radiol (NY) Jan. 2022;47(1):288–96. https://doi.org/10.1007/s00261-021-03296-1 .
doi: 10.1007/s00261-021-03296-1
Serai SD, Yin M. MR Elastography of the Abdomen: experimental protocols. Methods Mol Biol. 2021;2216:519–46. https://doi.org/10.1007/978-1-0716-0978-1_32 .
doi: 10.1007/978-1-0716-0978-1_32
pubmed: 33476022
pmcid: 9703236
Li LP, Tan H, Thacker JM, et al. Evaluation of Renal Blood Flow in chronic kidney Disease using arterial spin labeling perfusion magnetic resonance imaging. Kidney Int Rep Jan. 2017;2(1):36–43. https://doi.org/10.1016/j.ekir.2016.09.003 .
doi: 10.1016/j.ekir.2016.09.003
Brown RS, Sun MRM, Stillman IE, Russell TL, Rosas SE, Wei JL. The utility of magnetic resonance imaging for noninvasive evaluation of diabetic nephropathy. Nephrol Dial Transpl Jun. 2020;1(6):970–8. https://doi.org/10.1093/ndt/gfz066 .
doi: 10.1093/ndt/gfz066
Kannenkeril D, Janka R, Bosch A, et al. Detection of changes in renal blood Flow using arterial spin labeling MRI. Am J Nephrol. 2021;52(1):69–75. https://doi.org/10.1159/000513665 .
doi: 10.1159/000513665
pubmed: 33677438
Thurman J, Gueler F. Recent advances in renal imaging. F1000Res. 2018;7. https://doi.org/10.12688/f1000research.16188.1 .
Chhabra J, Karwarker GV, Rajamanuri M, et al. The role of arterial spin labeling functional MRI in assessing perfusion impairment of renal allografts: a systematic review. Cureus May. 2022;14(5):e25428. https://doi.org/10.7759/cureus.25428 .
doi: 10.7759/cureus.25428
Odudu A, Nery F, Harteveld AA et al. Arterial spin labelling MRI to measure renal perfusion: a systematic review and statement paper. Nephrol Dial Transplant. Sep 1. 2018;33(suppl_2):ii15-ii21. https://doi.org/10.1093/ndt/gfy180 .
Dekkers IA, de Boer A, Sharma K, et al. Consensus-based technical recommendations for clinical translation of renal T1 and T2 mapping MRI. Magma Feb. 2020;33(1):163–76. https://doi.org/10.1007/s10334-019-00797-5 .
doi: 10.1007/s10334-019-00797-5
Hueper K, Gutberlet M, Bräsen JH, et al. Multiparametric functional MRI: non-invasive imaging of inflammation and edema formation after kidney transplantation in mice. PLoS ONE. 2016;11(9):e0162705. https://doi.org/10.1371/journal.pone.0162705 .
doi: 10.1371/journal.pone.0162705
pubmed: 27632553
pmcid: 5025122
Sargsyan SA, Serkova NJ, Renner B, et al. Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int Jan. 2012;81(2):152–9. https://doi.org/10.1038/ki.2011.332 .
doi: 10.1038/ki.2011.332
Neugarten J. Renal BOLD-MRI and assessment for renal hypoxia. Kidney Int Apr. 2012;81(7):613–4. https://doi.org/10.1038/ki.2011.462 .
doi: 10.1038/ki.2011.462
Pruijm M, Milani B, Burnier M. Blood oxygenation level-dependent MRI to assess renal oxygenation in renal diseases: progresses and challenges. Front Physiol. 2016;7:667. https://doi.org/10.3389/fphys.2016.00667 .
doi: 10.3389/fphys.2016.00667
pubmed: 28105019
Inoue T, Kozawa E, Okada H, et al. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol Aug. 2011;22(8):1429–34. https://doi.org/10.1681/asn.2010111143 .
doi: 10.1681/asn.2010111143
Derlin T, Gueler F, Bräsen JH, et al. Integrating MRI and chemokine receptor CXCR4-Targeted PET for detection of leukocyte infiltration in complicated urinary tract infections after kidney transplantation. J Nucl Med Nov. 2017;58(11):1831–7. https://doi.org/10.2967/jnumed.117.193037 .
doi: 10.2967/jnumed.117.193037
Lesniak WG, Aboye T, Chatterjee S, Camarero JA, Nimmagadda S. In vivo evaluation of an Engineered Cyclotide as specific CXCR4 imaging reagent. Chem Oct. 2017;17(58):14469–75. https://doi.org/10.1002/chem.201702540 .
doi: 10.1002/chem.201702540
Borchert T, Beitar L, Langer LBN, et al. Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals. J Nucl Cardiol Aug. 2021;28(4):1636–45. https://doi.org/10.1007/s12350-019-01929-z .
doi: 10.1007/s12350-019-01929-z
Bruce R, Wentland AL, Haemel AK, et al. Incidence of nephrogenic systemic fibrosis using Gadobenate Dimeglumine in 1423 patients with renal insufficiency compared with Gadodiamide. Invest Radiol Nov. 2016;51(11):701–5. https://doi.org/10.1097/rli.0000000000000259 .
doi: 10.1097/rli.0000000000000259
Tyagi P, Moon CH, Janicki J, et al. Recent advances in imaging and understanding interstitial cystitis. F1000Res. 2018;7doi. https://doi.org/10.12688/f1000research.16096.1 .
Tailor V, Torella M, Manriquez V, Digesu GA. Understanding bladder pain syndrome/interstitial cystitis. Int Urogynecol J Aug. 2020;31(8):1495–6. https://doi.org/10.1007/s00192-020-04232-5 .
doi: 10.1007/s00192-020-04232-5
Bury MI, Fuller NJ, Meisner JW, et al. The promotion of functional urinary bladder regeneration using anti-inflammatory nanofibers. Biomaterials Nov. 2014;35(34):9311–21. https://doi.org/10.1016/j.biomaterials.2014.07.057 .
doi: 10.1016/j.biomaterials.2014.07.057
Nordling J, Anjum FH, Bade JJ, et al. Primary evaluation of patients suspected of having interstitial cystitis (IC). Eur Urol May. 2004;45(5):662–9. https://doi.org/10.1016/j.eururo.2003.11.021 .
doi: 10.1016/j.eururo.2003.11.021
Homma Y, Ueda T, Tomoe H, et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol Jul. 2009;16(7):597–615. https://doi.org/10.1111/j.1442-2042.2009.02326.x .
doi: 10.1111/j.1442-2042.2009.02326.x
Wong-You-Cheong JJ, Woodward PJ, Manning MA, Davis CJ. From the archives of the AFIP: inflammatory and nonneoplastic bladder masses: radiologic-pathologic correlation. Radiographics Nov-Dec. 2006;26(6):1847–68. https://doi.org/10.1148/rg.266065126 .
doi: 10.1148/rg.266065126
Jhang JF, Hsu YH, Ho HC, et al. Possible Association between bladder wall morphological changes on computed tomography and bladder-centered interstitial Cystitis/Bladder Pain Syndrome. Biomedicines Sep. 2021;24(10). https://doi.org/10.3390/biomedicines9101306 .
DeGeorge KC, Holt HR, Hodges SC. Bladder Cancer: diagnosis and treatment. Am Fam Physician Oct. 2017;15(8):507–14.
Tyagi P, Janicki J, Moon CH, Kaufman J, Chermansky C. Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1 mapping: applications in interstitial cystitis and beyond. Int Urol Nephrol Mar. 2018;50(3):401–9. https://doi.org/10.1007/s11255-018-1794-0 .
doi: 10.1007/s11255-018-1794-0
Paolone DR. Benign prostatic hyperplasia. Clin Geriatr Med. May 2010;26(2):223–39. https://doi.org/10.1016/j.cger.2010.02.010 .
Lloyd GL, Marks JM, Ricke WA. Benign Prostatic Hyperplasia and lower urinary tract symptoms: what is the role and significance of inflammation? Curr Urol Rep Aug. 2019;3(9):54. https://doi.org/10.1007/s11934-019-0917-1 .
doi: 10.1007/s11934-019-0917-1
Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms–what do we know? J Urol Dec. 2009;182(6 Suppl):S32–7. https://doi.org/10.1016/j.juro.2009.07.088 .
doi: 10.1016/j.juro.2009.07.088
Langan RC. Benign Prostatic Hyperplasia. Prim Care Jun. 2019;46(2):223–32. https://doi.org/10.1016/j.pop.2019.02.003 .
doi: 10.1016/j.pop.2019.02.003
Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: a Mini-review. Gerontology. 2019;65(5):458–64. https://doi.org/10.1159/000496289 .
doi: 10.1159/000496289
pubmed: 30943489
Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13(3):147–50.
pubmed: 22110398
Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS ONE. 2012;7(11):e49278. https://doi.org/10.1371/journal.pone.0049278 .
doi: 10.1371/journal.pone.0049278
pubmed: 23173053
Ma J, Gharaee-Kermani M, Kunju L, et al. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol Oct. 2012;188(4):1375–81. https://doi.org/10.1016/j.juro.2012.06.007 .
doi: 10.1016/j.juro.2012.06.007
Robert G, Descazeaud A, Nicolaïew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate Dec. 2009;1(16):1774–80. https://doi.org/10.1002/pros.21027 .
doi: 10.1002/pros.21027
Begley LA, Kasina S, MacDonald J, Macoska JA. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine Aug. 2008;43(2):194–9. https://doi.org/10.1016/j.cyto.2008.05.012 .
doi: 10.1016/j.cyto.2008.05.012
Powell T, Kellner D, Ayyagari R. Benign Prostatic Hyperplasia: clinical manifestations, imaging, and patient selection for prostate artery embolization. Tech Vasc Interv Radiol Sep. 2020;23(3):100688. https://doi.org/10.1016/j.tvir.2020.100688 .
doi: 10.1016/j.tvir.2020.100688
Kitzing YX, Prando A, Varol C, Karczmar GS, Maclean F, Oto A. Benign conditions that mimic prostate carcinoma: MR Imaging Features with histopathologic correlation. Radiographics Jan-Feb. 2016;36(1):162–75. https://doi.org/10.1148/rg.2016150030 .
doi: 10.1148/rg.2016150030
Lovegrove CE, Matanhelia M, Randeva J, et al. Prostate imaging features that indicate benign or malignant pathology on biopsy. Transl Androl Urol Sep. 2018;7(Suppl 4):S420–35. https://doi.org/10.21037/tau.2018.07.06 .
doi: 10.21037/tau.2018.07.06
Panzone J, Byler T, Bratslavsky G, Goldberg H. Transrectal ultrasound in prostate Cancer: current utilization, integration with mpMRI, HIFU and other emerging applications. Cancer Manag Res. 2022;14:1209–28. https://doi.org/10.2147/cmar.S265058 .
doi: 10.2147/cmar.S265058
pubmed: 35345605
Sigrist RMS, Liau J, Kaffas AE, Chammas MC, Willmann JK. Ultrasound Elastography: review of techniques and clinical applications. Theranostics. 2017;7(5):1303–29. https://doi.org/10.7150/thno.18650 .
doi: 10.7150/thno.18650
pubmed: 28435467
pmcid: 5399595
Correas JM, Tissier AM, Khairoune A, Khoury G, Eiss D, Hélénon O. Ultrasound elastography of the prostate: state of the art. Diagn Interv Imaging May. 2013;94(5):551–60. https://doi.org/10.1016/j.diii.2013.01.017 .
doi: 10.1016/j.diii.2013.01.017
Dias JL, Bilhim T. Modern imaging and image-guided treatments of the prostate gland: MR and ablation for cancer and prostatic artery embolization for benign prostatic hyperplasia. BJR Open. 2019;1(1):20190019. https://doi.org/10.1259/bjro.20190019 .
doi: 10.1259/bjro.20190019
pubmed: 33178947
pmcid: 7592499
Fennessy FM, Fedorov A, Gupta SN, Schmidt EJ, Tempany CM, Mulkern RV. Practical considerations in T1 mapping of prostate for dynamic contrast enhancement pharmacokinetic analyses. Magn Reson Imaging Nov. 2012;30(9):1224–33. https://doi.org/10.1016/j.mri.2012.06.011 .
doi: 10.1016/j.mri.2012.06.011
Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate Cancer. J Nucl Med Oct. 2017;58(10):1545–52. https://doi.org/10.2967/jnumed.117.191031 .
doi: 10.2967/jnumed.117.191031
Ghafoor S, Burger IA, Vargas AH. Multimodality imaging of prostate Cancer. J Nucl Med Oct. 2019;60(10):1350–8. https://doi.org/10.2967/jnumed.119.228320 .
doi: 10.2967/jnumed.119.228320
Schlemmer HP, Krause BJ, Schütz V, Bonekamp D, Schwarzenböck SM, Hohenfellner M. Imaging of prostate Cancer. Dtsch Arztebl Int Oct. 2021;22(42):713–9. https://doi.org/10.3238/arztebl.m2021.0309 .
doi: 10.3238/arztebl.m2021.0309
Evangelista L, Zattoni F, Cassarino G, et al. PET/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging Mar. 2021;48(3):859–73. https://doi.org/10.1007/s00259-020-05025-0 .
doi: 10.1007/s00259-020-05025-0